Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/82041Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Nuno Vale | |
| dc.creator | Paula Gomes | |
| dc.creator | Helder A Santos | |
| dc.date.accessioned | 2022-09-12T06:41:52Z | - |
| dc.date.available | 2022-09-12T06:41:52Z | - |
| dc.date.issued | 2013 | |
| dc.identifier.issn | 1389-2002 | |
| dc.identifier.other | sigarra:89175 | |
| dc.identifier.uri | https://hdl.handle.net/10216/82041 | - |
| dc.description.abstract | Ethionamide (ETH) is an important second-line antituberculosis drug used for the treatment of patients infected with multidrug-resistant Mycobacterium. Although ETH is a structural analogue of isoniazid (INH), both are pro-drugs that need to be activated by mycobacterial enzymes to exert their antimicrobial activity. ETH mechanism of action is thought to be identical to INH although the pathway of activation is distinct from that of INH. ETH is activated by an EthA enzyme, leading to the formation of an S-oxide metabolite that has considerably better activity than the parent drug. This review comprehensively examines the aspects related with the metabolism of ETH since its discovery up to today. | |
| dc.language.iso | eng | |
| dc.rights | openAccess | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
| dc.subject | Medicina básica | |
| dc.subject | Basic medicine | |
| dc.title | Metabolism of the Antituberculosis Drug Ethionamide | |
| dc.type | Artigo em Revista Científica Internacional | |
| dc.contributor.uporto | Faculdade de Ciências | |
| dc.identifier.authenticus | P-002-246 | |
| dc.subject.fos | Ciências médicas e da saúde::Medicina básica | |
| dc.subject.fos | Medical and Health sciences::Basic medicine | |
| Appears in Collections: | FCUP - Artigo em Revista Científica Internacional | |
This item is licensed under a Creative Commons License
